Liposomal doxorubicin plus radiofrequency ablation for complete necrosis of a hepatocellular carcinoma

C. W. Hong, S. K. Libutti, B. J. Wood

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Radiofrequency ablation (RFA) is a standard treatment for small, unresectable hepatocellular carcinomas (HCCS). However, rfa for larger tumours is less successful, and intravenous lyso-thermosensitive liposomal doxorubicin during rfa is one technique postulated to potentially address that limitation. This drug-plus-device combination therapy was used to completely treat a hcc in a patient who underwent liver transplantation 79 days later.

Original languageEnglish (US)
Pages (from-to)274-277
Number of pages4
JournalCurrent Oncology
Volume20
Issue number3
DOIs
StatePublished - 2013

Fingerprint

Hepatocellular Carcinoma
Necrosis
Liver Transplantation
Equipment and Supplies
Therapeutics
Pharmaceutical Preparations
Neoplasms
liposomal doxorubicin

Keywords

  • Ablation
  • Doxorubicin
  • Hepatocellular carcinoma
  • Liposomes
  • RFA

ASJC Scopus subject areas

  • Oncology

Cite this

Liposomal doxorubicin plus radiofrequency ablation for complete necrosis of a hepatocellular carcinoma. / Hong, C. W.; Libutti, S. K.; Wood, B. J.

In: Current Oncology, Vol. 20, No. 3, 2013, p. 274-277.

Research output: Contribution to journalArticle

Hong, C. W. ; Libutti, S. K. ; Wood, B. J. / Liposomal doxorubicin plus radiofrequency ablation for complete necrosis of a hepatocellular carcinoma. In: Current Oncology. 2013 ; Vol. 20, No. 3. pp. 274-277.
@article{92066ee56d56469a99a2fc607f6ae0ef,
title = "Liposomal doxorubicin plus radiofrequency ablation for complete necrosis of a hepatocellular carcinoma",
abstract = "Radiofrequency ablation (RFA) is a standard treatment for small, unresectable hepatocellular carcinomas (HCCS). However, rfa for larger tumours is less successful, and intravenous lyso-thermosensitive liposomal doxorubicin during rfa is one technique postulated to potentially address that limitation. This drug-plus-device combination therapy was used to completely treat a hcc in a patient who underwent liver transplantation 79 days later.",
keywords = "Ablation, Doxorubicin, Hepatocellular carcinoma, Liposomes, RFA",
author = "Hong, {C. W.} and Libutti, {S. K.} and Wood, {B. J.}",
year = "2013",
doi = "10.3747/co.20.1266",
language = "English (US)",
volume = "20",
pages = "274--277",
journal = "Current Oncology",
issn = "1198-0052",
publisher = "Multimed Inc.",
number = "3",

}

TY - JOUR

T1 - Liposomal doxorubicin plus radiofrequency ablation for complete necrosis of a hepatocellular carcinoma

AU - Hong, C. W.

AU - Libutti, S. K.

AU - Wood, B. J.

PY - 2013

Y1 - 2013

N2 - Radiofrequency ablation (RFA) is a standard treatment for small, unresectable hepatocellular carcinomas (HCCS). However, rfa for larger tumours is less successful, and intravenous lyso-thermosensitive liposomal doxorubicin during rfa is one technique postulated to potentially address that limitation. This drug-plus-device combination therapy was used to completely treat a hcc in a patient who underwent liver transplantation 79 days later.

AB - Radiofrequency ablation (RFA) is a standard treatment for small, unresectable hepatocellular carcinomas (HCCS). However, rfa for larger tumours is less successful, and intravenous lyso-thermosensitive liposomal doxorubicin during rfa is one technique postulated to potentially address that limitation. This drug-plus-device combination therapy was used to completely treat a hcc in a patient who underwent liver transplantation 79 days later.

KW - Ablation

KW - Doxorubicin

KW - Hepatocellular carcinoma

KW - Liposomes

KW - RFA

UR - http://www.scopus.com/inward/record.url?scp=84878764831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878764831&partnerID=8YFLogxK

U2 - 10.3747/co.20.1266

DO - 10.3747/co.20.1266

M3 - Article

VL - 20

SP - 274

EP - 277

JO - Current Oncology

JF - Current Oncology

SN - 1198-0052

IS - 3

ER -